erlotinib hydrochloride has been researched along with Gastroduodenal Ulcer in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kim, YH; Masago, K; Mishima, M | 1 |
Argiris, A; Basu, S; Bonomi, P; Buckingham, L; Coon, J; Fidler, MJ; Johnson, DH; Kaiser, K; Patel, JD; Sandler, A; Villaflor, VM | 1 |
1 trial(s) available for erlotinib hydrochloride and Gastroduodenal Ulcer
Article | Year |
---|---|
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gastrointestinal Hemorrhage; Humans; Immunohistochemistry; In Situ Hybridization; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mutation; Peptic Ulcer; Predictive Value of Tests; Pyrazoles; Quinazolines; Sulfonamides | 2008 |
1 other study(ies) available for erlotinib hydrochloride and Gastroduodenal Ulcer
Article | Year |
---|---|
Erlotinib and gastrointestinal ulcer.
Topics: Aged; ErbB Receptors; Erlotinib Hydrochloride; Female; Gastrointestinal Diseases; Humans; Male; Peptic Ulcer; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |